Experiences with
Cetuximab2,493 public posts
Want to take advantage of all our features? Just log in!
or
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL. The previously approved BTKi drugs (acalabrutinib, ibrutinib and zanubrutinib) bond covalently. Eventually, these drugs can stop inhibiting CLL, when DNA changes in the BTK enzyme prevent the BTKi from